ClinicalTrials.gg
TerminatedNCT01381549Updated Sep 8, 2017Results posted

GSK2251052 in Complicated Urinary Tract Infection

A Phase 2 interventional study of GSK2251052 and imipenem-cilastatin in Infections, Urinary Tract, sponsored by GlaxoSmithKline. Terminated at 24 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-09-08.

Sponsored by GlaxoSmithKline · Phase 2, Interventional, and Treatment

Why this study was terminated
Microbiological findings of resistance on therapy in patients with complicated urinary tract infection

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
20
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 14 studies in Urinary Tract Infections by GlaxoSmithKline — 4 open to participants now, 4 under way, none of them phase 3. Urinary Tract Infections · GlaxoSmithKline.

Enrollment
12th of 13
20 · median 61
Started
2011
the only one that year
Phase 2
2 of 14
none open now
Registered
1st of 14
by date

Among the 14 studies in Urinary Tract Infections by GlaxoSmithKline, this one is the 12th largest by enrollment of the 13 interventional ones that give a count, is the only one that started in 2011, is one of 2 in phase 2, and was the 1st registered.

Urinary Tract Infections

804 studies on the registry are indexed under Urinary Tract Infections; 133 are open to participants now.

Browse Urinary Tract Infections studies →

Open to participants now

4 of the 14 studies in Urinary Tract Infections by GlaxoSmithKline are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Who these studies take

Of the 84 Urinary Tract Infections studies recruiting now, 50 (60%) set no upper age limit and 23 (27%) stop at 75 or younger; 15 take children under 18; 17 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Urinary Tract Infections by GlaxoSmithKline, or all of them as a file.
02

Study summary

This study is being conducted to evaluate the safety, efficacy (clinical and microbiological), pharmacokinetics/pharmacodynamics of GSK2251052 and to assess whether it would be a suitable antibiotic for the treatment for febrile lower cUTI and pyelonephritis(complicated and uncomplicated). GSK2251052 will be compared to imipenem-cilastatin, which is an antibiotic commonly used to treat serious cUTI infections. GSK2251052 has a spectrum of microbiological activity that includes pathogens responsible for cUTI.

03

Conditions studied

  • Infections, Urinary Tract

Keywords

  • Gram-negative
  • uropathogens
  • complicated lower urinary tract infection
  • pyelonephritis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult subjects least 18 years of age.

N.B. Females of non-childbearing or may be enrolled. Females of childbearing potential must have a negative pregnancy test at study entry and must have practiced adequate for at least 30 days prior to study entry. Additionally, the subject agrees to one of the following methods for avoidance of pregnancy during the entire study treatment period:

  • Abstinence; or,
  • Oral Contraceptive, either combined estrogen/progesterone or progesterone alone, PLUS an additional barrier method [ie, condom, occlusive cap (diaphragm or cervical/vault caps) or vaginal spermicidal agent (foam/gel/film/cream/suppository)]; or,
  • Injectable progesterone; or
  • Implants of levonorgestrel; or,
  • Estrogenic vaginal ring; or,
  • Percutaneous contraceptive patches; or
  • Intrauterine device (IUD) or intrauterine system (IUS) showing that failure rate is less than 1% in the IUD or IUS product label; or,
  • Has a male partner who is sterilized (vasectomy with documentation of azoospermia).
  • Double barrier method: condom and an occlusive cap (diaphragm or cervical/vault caps) with a vaginal spermicidal agent (foam/gel/film/cream/suppository)
  • Females are considered to be of non-childbearing potential if they have documented tubal ligation or hysterectomy; or are , defined as 12 months of spontaneous amenorrhea [in questionable cases a blood sample with simultaneous follicle stimulating hormone (FSH) > 40 MlU/ml and estradiol \< 40 pg/ml (\<147 pmol/L) is confirmatory]
  • Subject requires hospitalisation and has clinical signs and symptoms of lower cUTI or pyelonephritis (complicated or uncomplicated) as defined below, that requires parenteral treatment only with a treatment course of a minimum of 5 days and a maximum of 14 days:
  • Lower cUTI - subjects must have documented fever defined as >38°C oral, >38.5°C tympanic or >39°C rectal, within the last 24 hours exceptions would be:
  • Afebrile subjects with lower cUTI who have a white blood cell count (WBC) ≥15,000 cells/mm3
  • Afebrile subjects with a lower cUTI following requiring parenteral therapy due to a specific indication e.g. before and during an operative procedure, when oral antibiotics are not indicated or in cases where the cUTI is suspected to be due to a pathogen resistant to current oral antibiotics
  • and at least two of the following UTI symptoms including dysuria, frequency, urgency or suprapubic pain, with the presence of a complicating factor:
  • Male gender;
  • Current bladder instrumentation or indwelling urinary catheter that has to be removed two days before the end of IV study drug administration;
  • Obstructive uropathy that is expected to be medically or surgically treated during the course of IV study drug administration;
  • Urogenital surgery within 7 days preceding administration of the first dose of study drug;
  • Functional or anatomical abnormality of the urogenital tract including anatomic malformations or neurogenic bladder with voiding disturbance of at least 100 mL residual urine.
  • Acute pyelonephritis (complicated or uncomplicated): subjects must have documented fever defined as >38°C oral, >38.5°C tympanic or >39°C rectal, within the last 24 hours and flank pain or costovertebral angle tenderness (CVA). Complicating factors for pyelonephritis are the same as for complicated UTI.
  • Subject has pyuria (white blood cell [WBC] count > 10/µL (or >5/high-power field [HPF] in a conventional urinalysis) in unspun clean-catch midstream urine (MSU) or catheter urine sample or >= 10 WBC/HPF in spun MSU or catheter urine).
  • Subject has Gram-negative organism(s) on direct examination of a Gram-stained specimen from unspun or spun MSU or catheter urine sample.
  • Subject has provided a pre-therapy urine specimen obtained within 48 hours prior to the start of therapy, which when cultured has grown at least one and not more than two Gram-negative uropathogens at >=10\^5 CFU/mL.
  • A subject may be enrolled before the results of the pre-therapy urine culture is known, but the subject should be withdrawn from the study if the culture does not yield at least one but not more than two qualifying Gram-negative uropathogens at >=10\^5 CFU/mL or if the culture yields Gram-positive uropathogens.
  • A subject with lower cUTI or pyelonephritis (complicated or uncomplicated) who has failed a previous antibacterial treatment regimen is eligible provided a urine specimen is positive for one and not more than two bacterial Gram-negative uropathogens at >=10\^5 CFU/mL. Subjects who are treatment failures due to imipenem-cilastatin should not be enrolled.
  • or QTcF \< 450 msec; or QTc \< 480 msec in subjects with Bundle Branch Block

Exclusion criteria

Subjects meeting any of the following criteria must not be enrolled in the study:

  • Concomitant infection requiring systemic antibacterial therapy other than study drugs at the time of randomisation.
  • Subject is known to have one or more of the following:
  • A urinary catheter that is not being removed during the study (or with an expectation that a catheter would be inserted during therapy with study drug and subsequently not removed during the study period; (intermittent straight catheterisation is acceptable)
  • Complete permanent obstruction of the urinary tract;
  • A permanent indwelling catheter or comparable instrumentation including nephrostomy that will not be removed during IV study drug administration
  • Suspected or confirmed prostatitis
  • Suspected or confirmed perinephric or intrarenal abscess
  • A UTI suspected or confirmed to be fungal in origin (with >= 10\^3 fungal CFU/mL)
  • A UTI suspected or confirmed to be due to a Gram-positive uropathogen(s), with >= 10\^5 Gram-positive organism CFU/mL;
  • A UTI known at study entry to be caused by a pathogen(s) resistant to the study antimicrobial agent;
  • Known ileal loops or vesico-ureteral reflux ;
  • Polycystic kidney disease.
  • Subject has an APACHE II score >20
  • Subject has known severe impairment of renal function including: a calculated (CrCl) of less than 50 mL/min; requirement for peritoneal dialysis, haemodialysis, or haemofiltration; oliguria (less than 20 mL urine output per hour over 24 hours);
  • Subject with an intractable lower cUTI requiring more than 14 Days IV treatment.
  • Subjects with asymptomatic lower cUTI, such as subjects with spinal cord injury with lower cUTI who are not able to perceive symptoms due to their injury.
  • Subject with lower cUTI or pyelonephritis (complicated and uncomplicated) who has received any amount of a potentially therapeutic antibiotic within the 96 h before providing the baseline urine culture specimen or prior to the start of the study.
  • Subject has Gram-positive organism(s) on direct examination of a Gram-stained specimen of spun/unspun MSU or catheter urine.
  • Subject is considered unlikely to survive the 4 6 week study period or has any rapidly progressing disease or immediately life-threatening illness (including acute hepatic failure, respiratory failure or septic shock).
  • Subject has evidence of known or pre-existing severe hepatic disease ( score of B or C).
  • Subject has a known baseline less than 10 g/dL ,haematocrit less than 30% and/or a known reticulocyte count of >5% (i.e., reticulocytes >5% of total RBC mass)
  • Subject has known neutropenia or is anticipated to develop neutropenia during the course of the study (i.e., new chemotherapy subject), with less than 1000 cells/mm3
  • Subject has a known count less than 75,000 cells /mm3 (subjects with platelet counts as low as 50,000 cells /mm3 are eligible if the reduction is historically stable).
  • Subject has an immunocompromising illness; including known (HIV) infection or acquired immunodeficiency syndrome (AIDS), organ (including bone marrow) transplantation, hematological , and/or therapy , including high-dose (e.g., greater than 40 mg prednisone or equivalent per day for greater than two weeks)
  • Subject has participated in any drug or device study within 30 days of study entry or within 5 half-lives, whichever is longer.
  • Subject has previously received treatment with GSK2251052.
  • Subject has a prior history of seizures or has a CNS abnormality predisposing them to seizures or has a lowered seizure threshold and/or is using concomitant medications with seizure potential.
  • Subject requires probenicid or valproic acid medications.
  • Subject has a history of moderate or severe to beta-lactam antibiotics.
  • Subject is pregnant or nursing
  • Subject, in the opinion of the investigator may be significantly compromised by a potential drop in haemoglobin ≥2.5g/dl which is not related to the condition under study
  • French subjects: the French subject has participated in any study using an investigational drug during the previous 30 days
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
20 participants (actual)

Study arms

  • Experimental
    GSK2251052 750mg

    q12h administered via IV infusion, plus saline placebo

    Drug: GSK2251052 · Other: Placebo

  • Experimental
    GSK2251052 1500mg

    q12h administered via IV infusion, plus saline placebo

    Drug: GSK2251052 · Other: Placebo

  • Active comparator
    imipenem-cilastatin

    500 mg imipenem monohydrate and 500 mg cilastatin sodium; q6h administered via IV infusion, plus saline placebo

    Drug: imipenem-cilastatin · Other: Placebo

Interventions

  • Reconstituted, added to 250mL 0.9% NaCl solution and administered via IV infusion

  • Drugimipenem-cilastatin

    Prepare as per prescribing information instructions in 100 mL bag of 0.9% NaCl and administered via IV infusion

    Also known as: Primaxin® (Manufacturer: Merck)

  • OtherPlacebo

    saline placebo

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Clinical Laboratory Parameters- Albumin and Total Protein

    Clinical laboratory parameters included albumin and total protein. Baseline was Day 1. Change from Baseline was calculated by subtracting Baseline values from individual post-Baseline values. Mean change from Baseline up to Late follow-up visit in albumin and total protein are presented.

    Time frame: Baseline (Day 1) to Late Follow up Visit (21 to 28 days post-IV therapy)

  2. Change From Baseline in Clinical Laboratory Parameters- Creatinine Clearance, Estimated (CCE)

    Clinical laboratory parameters included CCE. Baseline was Day 1. Change from Baseline was calculated by subtracting Baseline values from individual post-Baseline values. Mean change from Baseline up to Late follow-up visit in CCE are presented.

    Time frame: Baseline (Day 1) to Late Follow up Visit (21 to 28 days post-IV therapy)

  3. Change From Baseline in Clinical Laboratory Parameters- Creatinine, Direct Bilirubin and Total Bilirubin

    Clinical laboratory parameters included creatinine, direct bilirubin and total bilirubin. Baseline was Day 1. Change from Baseline was calculated by subtracting Baseline values from individual post-Baseline values. Mean change from Baseline up to Late follow-up visit in creatinine, direct bilirubin and total bilirubin are presented.

    Time frame: Baseline (Day 1) to Late Follow up Visit (21 to 28 days post-IV therapy)

  4. Change From Baseline in Clinical Laboratory Parameters- Calcium, Carbon-dioxide (C02) Content/Bicarbonate, Chloride, Glucose, Potassium, Sodium and Urea/Blood Urea Nitrogen (BUN)

    Clinical laboratory parameters included C02 content/bicarbonate, chloride, glucose, potassium, sodium and urea/BUN. Baseline was Day 1. Change from Baseline was calculated by subtracting Baseline values from individual post-Baseline values. Mean change from Baseline up to Late follow-up visit in C02 content/bicarbonate, chloride, glucose, potassium, sodium and urea/BUN are presented.

    Time frame: Baseline (Day 1) to Late Follow up Visit (21 to 28 days post-IV therapy)

  5. Change From Baseline in Clinical Laboratory Parameters- Alanine Amino Transferase (ALT), Alkaline Phosphatase (ALP), Aspartate Amino Transferase (AST), Creatine Kinase and Gamma Glutamyl Transferase (GGT)

    Clinical laboratory parameters included ALT, ALP, AST, Creatine kinase and GGT. Baseline was Day 1. Change from Baseline was calculated by subtracting Baseline values from individual post-Baseline values. Mean change from Baseline up to Late follow-up visit in ALT, ALP, AST, Creatine kinase and GGT are presented.

    Time frame: Baseline (Day 1) to Late Follow up Visit (21 to 28 days post-IV therapy)

  6. Number of Participants With Adverse Events (AE) and Serious Adverse Events (SAE)

    AE is any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product. For marketed medicinal products, this also includes failure to produce expected benefits (i.e., lack of efficacy), abuse or misuse. SAE is any untoward medical occurrence that, at any dose results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, or is a congenital anomaly/birth defect or is medically significant.

    Time frame: Up to 28 days post-therapy

  7. Number of Participants With Abnormal Electrocardiogram (ECG) Findings

    Twelve lead ECGs were obtained during the study using an ECG machine that automatically measured PR, QRS, QT, and QT corrected by Bazett's formula (QTcB), QT corrected by Fridericia's formula (QTcF) intervals. Twelve lead ECGs were performed with the participant in a semi-supine position having rested in this position for at least 10 minutes beforehand. Measurements that deviated substantially from previous readings were repeated immediately. Three measurements were taken at pre-dose on Day 1 at least 5 min apart. One additional ECG measurement was taken after completion of the first infusion of study medication. Two ECG measurements (pre and post-1st infusion of the day) were taken on Day 4 while the participant was on IV therapy. When there was an abnormal finding, two more were taken and the mean PR interval, QRS duration, QT interval and QTcB were calculated from automated ECG readings. One ECG measurement was taken at the early safety follow-up visit.

    Time frame: Up to Late Follow-up Visit (21 to 28 days post-IV therapy)

  8. Summary of Vital Signs: Mean Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)

    Vital sign measurements included SBP and DBP (supine or semi-supine). Measurements that deviated substantially from previous readings were repeated immediately. Mean SBP and DBP are presented.

    Time frame: Up to Late Follow up Visit (21 to 28 days post-IV therapy)

  9. Summary of Vital Signs- Mean Heart Rate

    Vital sign measurements included heart rate. Measurements that deviated substantially from previous readings were repeated immediately. Mean heart rate is presented.

    Time frame: Up to Late Follow-up Visit (21 to 28 days post-IV therapy)

  10. Summary of Vital Signs- Mean Respiration Rate

    Vital sign measurements included respiratory rate. Measurements that deviated substantially from previous readings were repeated immediately. Mean respiration rate are presented.

    Time frame: Up to Late Follow-up Visit (21 to 28 days post-IV therapy)

  11. Summary of Vital Signs- Mean Temperature

    Vital sign measurements included temperature (oral, tympanic or rectal). Measurements that deviated substantially from previous readings were repeated immediately. Temperature was assessed as normal hospital practice dictated and the maximum daily temperature was recorded in the electronic case report form (eCRF).

    Time frame: Up to Late Follow up Visit (21 to 28 days post-IV therapy)

  12. Therapeutic Response at the Test of Cure Visit

    The therapeutic response was the combination of a participant's clinical and microbiological response. It was assessed at the Test of Cure visit in participants who have a qualifying Gram-negative uropathogen at Baseline and have had a minimum of 5 days of IV therapy. Therapeutic response was a measure of the overall efficacy response, and a therapeutic success referred to participants who have been deemed both a 'clinical success' and a 'microbiological success'. All other combinations (other than 'clinical success' + 'microbiological success') were deemed failures for therapeutic response.

    Time frame: Test of Cure Visit (5 to 9 days post-IV therapy)

  13. Change From Baseline in Hematology Parameters- Hematocrit

    Hematology parameters included hematocrit. Baseline was Day 1. Change from Baseline was calculated by subtracting Baseline values from individual post-Baseline values. Mean change from Baseline up to Late follow-up visit in hematocrit are presented.

    Time frame: Baseline (Day 1) to Late Follow up Visit (21 to 28 days post-IV therapy)

  14. Change From Baseline in Hematology Parameters- Mean Corpuscle Hemoglobin (MCH)

    Hematology parameters included MCH. Baseline was Day 1. Change from Baseline was calculated by subtracting Baseline values from individual post-Baseline values. Mean change from Baseline up to Late follow-up visit in MCH are presented.

    Time frame: Baseline (Day 1) to Late Follow up Visit (21 to 28 days post-IV therapy)

  15. Change From Baseline in Hematology Parameters- Mean Corpuscle Volume (MCV)

    Hematology parameters included MCV. Baseline was Day 1. Change from Baseline was calculated by subtracting Baseline values from individual post-Baseline values. Mean change from Baseline up to Late follow-up visit in MCV are presented.

    Time frame: Baseline (Day 1) to Late Follow up Visit (21 to 28 days post-IV therapy)

  16. Change From Baseline in Hematology Parameters- Red Blood Cell (RBC) Count and Reticulocytes

    Hematology parameters included RBC count and reticulocytes. Baseline was Day 1. Change from Baseline was calculated by subtracting Baseline values from individual post-Baseline values. Mean change from Baseline up to Late follow-up visit in RBC count and reticulocytes are presented.

    Time frame: Baseline (Day 1) to Late Follow up Visit (21 to 28 days post-IV therapy)

  17. Change From Baseline in Hematology Parameters- Hemoglobin and Mean Corpuscle Hemoglobin Concentration (MCHC)

    Hematology parameters included hemoglobin and MCHC. Baseline was Day 1. Change from Baseline was calculated by subtracting Baseline values from individual post-Baseline values. Mean change from Baseline up to Late follow-up visit in hemoglobin and MCHC are presented.

    Time frame: Baseline (Day 1) to Late Follow up Visit (21 to 28 days post-IV therapy)

  18. Change From Baseline in Hematology Parameters- Basophils, Eosinophils, Lymphocytes, Monocytes, Platelet Count, Total Neutrophils and White Blood Cell Count (WBC)

    Hematology parameters included basophils, eosinophils, lymphocytes, monocytes, platelet count, total neutrophils and WBC. Baseline was Day 1. Change from Baseline was calculated by subtracting Baseline values from individual post-Baseline values. Mean change from Baseline up to Late follow-up visit in basophils, eosinophils, lymphocytes, monocytes, platelet count, total neutrophils and WBC are presented.

    Time frame: Baseline (Day 1) to Late Follow up Visit (21 to 28 days post-IV therapy)

Secondary outcomes

  1. Microbiological Response at the End of IV Therapy Visit, Test of Cure Visit and Late Follow-Up Visit

    Microbiological response involved both microbiological success and microbiological failure. A reduction in the uropathogens in the urine culture and no growth on blood culture was termed as microbiological success. Increase in the uropathogens in the urine culture and pathogens identified in the blood culture or use of antibacterials other than study treatments were classified as microbiological failures.

    Time frame: End of IV therapy (0-24 hours post-therapy), Test of Cure Visit (5 to 9 days post-IV therapy) and Late Follow-up (21-28 days post-therapy)

  2. Clinical Response at the End of IV Therapy Visit, Test of Cure Visit and Late Follow-Up Visit

    Clinical response was a combination of clinical success and clinical failure. In clinical success, participants showed no signs and symptoms of pyelonephritis and lower complicated urinary tract infection and antibiotics are not used for the same. In clinical failure, there is reappearance of signs and symptoms of and lower complicated urinary tract infection and participant required antibiotics for the same.

    Time frame: End of IV therapy (0-24 hours post-therapy), Test of Cure Visit (5 to 9 days post-IV therapy) and Late Follow-up (21-28 days post-therapy)

  3. Therapeutic Response (Combined Clinical and Microbiological Response) at the End of IV Visit and Late Follow-Up Visit

    The therapeutic response was the combination of a participant's clinical and microbiological response. It was assessed at the Test of Cure visit in participants who have a qualifying Gram-negative uropathogen at Baseline and have had a minimum of 5 days of IV therapy. Therapeutic response was a measure of the overall efficacy response, and a therapeutic success referred to participants who have been deemed both a 'clinical success' and a 'microbiological success'. All other combinations (other than 'clinical success' + 'microbiological success') were deemed failures for therapeutic response.

    Time frame: End of IV therapy (0-24 hours post-therapy) and Late Follow-up (21-28 days post-therapy)

  4. Maximum Plasma Concentration (Cmax) of GSK2251052

    The planned pharmacokinetic (PK) and PK/pharmacodynamic analyses were not performed, because the PK data was not collected.

    Time frame: Day 3: Pre- dose (just prior to the start of the first infusion of the day) and 1 hour (just prior to the end of the infusion), 2, 4, and 12 hours post-dose

  5. Area Under the Concentration Time Curve (AUC) of GSK2251052

    The planned pharmacokinetic (PK) and PK/pharmacodynamic analyses were not performed, because the PK data was not collected.

    Time frame: Day 3: Pre- dose (just prior to the start of the first infusion of the day) and 1 hour (just prior to the end of the infusion), 2, 4, and 12 hours post-dose

  6. Time to Cmax (Tmax) of GSK2251052

    The planned pharmacokinetic (PK) and PK/pharmacodynamic analyses were not performed, because the PK data was not collected.

    Time frame: Day 3: Pre- dose (just prior to the start of the first infusion of the day) and 1 hour (just prior to the end of the infusion), 2, 4, and 12 hours post-dose

  7. Cmax of GSK2251052 Using Non-intensive PK Sampling

    The planned pharmacokinetic (PK) and PK/pharmacodynamic analyses were not performed, because the PK data was not collected.

    Time frame: Day 4: Pre- dose (just prior to the start of the first infusion of the day) and 1 hour (just prior to the end of the infusion), 2, 4, and 12 hours post-dose

  8. AUC of GSK2251052 Using Non-intensive PK Sampling

    The planned pharmacokinetic (PK) and PK/pharmacodynamic analyses were not performed, because the PK data was not collected.

    Time frame: Day 4: Pre- dose (just prior to the start of the first infusion of the day) and 1 hour (just prior to the end of the infusion), 2, 4, and 12 hours post-dose

  9. Tmax of GSK2251052 Using Non-intensive PK Sampling

    The planned pharmacokinetic (PK) and PK/pharmacodynamic analyses were not performed, because the PK data was not collected.

    Time frame: Day 4: Pre- dose (just prior to the start of the first infusion of the day) and 1 hour (just prior to the end of the infusion), 2, 4, and 12 hours post-dose

  10. Cmax of GSK2251052 Using Intensive PK Sampling

    The planned pharmacokinetic (PK) and PK/pharmacodynamic analyses were not performed, because the PK data was not collected.

    Time frame: Day 4: Pre-dose (just prior to the start of the first infusion of the day) 0.5, 1 hour (just prior to the end of the infusion), 1.25, 1.5, 2, 3, 4, 8 and 12 hours post-dose

  11. AUC of GSK2251052 Using Intensive PK Sampling

    The planned pharmacokinetic (PK) and PK/pharmacodynamic analyses were not performed, because the PK data was not collected.

    Time frame: Day 4: Pre-dose (just prior to the start of the first infusion of the day) 0.5, 1 hour (just prior to the end of the infusion), 1.25, 1.5, 2, 3, 4, 8 and 12 hours post-dose

  12. Tmax of GSK2251052 Using Intensive PK Sampling

    The planned pharmacokinetic (PK) and PK/pharmacodynamic analyses were not performed, because the PK data was not collected.

    Time frame: Day 4: Pre-dose (just prior to the start of the first infusion of the day) 0.5, 1 hour (just prior to the end of the infusion), 1.25, 1.5, 2, 3, 4, 8 and 12 hours post-dose

07

Results

Posted Sep 8, 2017

Participant flow

This study was conducted at eight centers in three countries (United States, Spain and Greece) from 28-June-2011 to 06-March-2012. A total of 20 participants were randomized in the study.

Participant flow — Overall Study
MilestoneGSK2251052 750 mgGSK2251052 1500 mgImipenem-Cilastatin
Started686
Completed685
Not completed001
Withdrew: Ineligible: no organisms isolated001

Outcome measures

PrimaryChange From Baseline in Clinical Laboratory Parameters- Albumin and Total Protein

Clinical laboratory parameters included albumin and total protein. Baseline was Day 1. Change from Baseline was calculated by subtracting Baseline values from individual post-Baseline values. Mean change from Baseline up to Late follow-up visit in albumin and total protein are presented.

Time frame:
Baseline (Day 1) to Late Follow up Visit (21 to 28 days post-IV therapy)
Reported as:
Mean · Gram per Liter
Change From Baseline in Clinical Laboratory Parameters- Albumin and Total Protein
Gram per LiterGSK2251052 750 mgGSK2251052 1500 mgImipenem-Cilastatin
Albumin: On IV therapy (Day 5)-0.5 ± 4.85-3.8 ± 7.09-0.3 ± 3.06
Albumin: On IV therapy (Day 11)2.0 ± NA——
Albumin: End of IV therapy1.0 ± 4.69-2.1 ± 7.380.8 ± 3.31
Albumin: Test of Cure5.7 ± 3.671.7 ± 5.792.6 ± 2.61
Albumin: Early Follow-up8.2 ± 2.773.5 ± 3.393.4 ± 3.65
Albumin: Late Follow-up7.3 ± 4.933.5 ± 4.593.2 ± 3.77
Total protein: On IV therapy (Day 5)0.0 ± 8.17-5.0 ± 9.091.0 ± 6.24
Total protein: On IV therapy (Day 11)-5.0 ± NA——
Total protein: End of IV therapy-0.4 ± 9.76-3.3 ± 10.143.0 ± 6.69
Total protein: Test of Cure5.8 ± 7.682.1 ± 6.896.4 ± 3.29
Total protein: Early Follow-up9.4 ± 5.135.3 ± 3.276.4 ± 4.98
Total protein: Late Follow-up8.2 ± 4.925.3 ± 6.284.8 ± 5.40
PrimaryChange From Baseline in Clinical Laboratory Parameters- Creatinine Clearance, Estimated (CCE)

Clinical laboratory parameters included CCE. Baseline was Day 1. Change from Baseline was calculated by subtracting Baseline values from individual post-Baseline values. Mean change from Baseline up to Late follow-up visit in CCE are presented.

Time frame:
Baseline (Day 1) to Late Follow up Visit (21 to 28 days post-IV therapy)
Reported as:
Mean · Milliliter per minute
Change From Baseline in Clinical Laboratory Parameters- Creatinine Clearance, Estimated (CCE)
Milliliter per minuteGSK2251052 750 mgGSK2251052 1500 mgImipenem-Cilastatin
CCE: On IV therapy (Day 5)—18.0 ± NA—
CCE: Test of Cure2.0 ± NA13.0 ± NA56.0 ± NA
CCE: Early Follow-up1.0 ± NA21.0 ± NA60.0 ± NA
CCE: Late Follow-up25.0 ± NA21.0 ± NA—
PrimaryChange From Baseline in Clinical Laboratory Parameters- Creatinine, Direct Bilirubin and Total Bilirubin

Clinical laboratory parameters included creatinine, direct bilirubin and total bilirubin. Baseline was Day 1. Change from Baseline was calculated by subtracting Baseline values from individual post-Baseline values. Mean change from Baseline up to Late follow-up visit in creatinine, direct bilirubin and total bilirubin are presented.

Time frame:
Baseline (Day 1) to Late Follow up Visit (21 to 28 days post-IV therapy)
Reported as:
Mean · Micromole per liter
Change From Baseline in Clinical Laboratory Parameters- Creatinine, Direct Bilirubin and Total Bilirubin
Micromole per literGSK2251052 750 mgGSK2251052 1500 mgImipenem-Cilastatin
Creatinine: On IV therapy (Day 5)-4.20 ± 10.347-5.78 ± 13.336-11.97 ± 10.279
Creatinine: On IV therapy (Day 11)-1.50 ± NA——
Creatinine: End of IV therapy-0.24 ± 13.616-11.26 ± 12.634-8.70 ± 9.426
Creatinine: Test of Cure-2.17 ± 7.238-9.66 ± 11.743-8.54 ± 9.816
Creatinine: Early Follow-up-3.90 ± 6.1342.88 ± 14.662-4.56 ± 11.138
Creatinine: Late Follow-up4.43 ± 6.960-5.22 ± 10.760-5.22 ± 11.228
Total bilirubin: On IV therapy (Day 3)-7.5 ± 10.73-4.9 ± 4.45-7.2 ± 6.42
Total bilirubin: On IV therapy (Day 5)-7.0 ± 10.18-3.5 ± 5.57-7.3 ± 8.50
Total bilirubin: On IV therapy (Day 8)-5.0 ± NA-4.5 ± 0.71-1.0 ± NA
Total bilirubin: On IV therapy (Day 11)-1.0 ± NA——
Total bilirubin: End of IV therapy-8.2 ± 11.37-5.6 ± 0.71-5.5 ± 6.16
Total bilirubin: Test of Cure-7.7 ± 9.14-4.7 ± 5.00-6.4 ± 7.64
Total bilirubin: Early Follow-up-6.2 ± 8.29-4.5 ± 3.39-6.0 ± 7.04
Total bilirubin: Late Follow-up-5.2 ± 8.73-4.8 ± 4.12-5.0 ± 4.80
PrimaryChange From Baseline in Clinical Laboratory Parameters- Calcium, Carbon-dioxide (C02) Content/Bicarbonate, Chloride, Glucose, Potassium, Sodium and Urea/Blood Urea Nitrogen (BUN)

Clinical laboratory parameters included C02 content/bicarbonate, chloride, glucose, potassium, sodium and urea/BUN. Baseline was Day 1. Change from Baseline was calculated by subtracting Baseline values from individual post-Baseline values. Mean change from Baseline up to Late follow-up visit in C02 content/bicarbonate, chloride, glucose, potassium, sodium and urea/BUN are presented.

Time frame:
Baseline (Day 1) to Late Follow up Visit (21 to 28 days post-IV therapy)
Reported as:
Mean · Millimole per Liter
Change From Baseline in Clinical Laboratory Parameters- Calcium, Carbon-dioxide (C02) Content/Bicarbonate, Chloride, Glucose, Potassium, Sodium and Urea/Blood Urea Nitrogen (BUN)
Millimole per LiterGSK2251052 750 mgGSK2251052 1500 mgImipenem-Cilastatin
Calcium: On IV therapy (Day 5)0.082 ± 0.1664-0.112 ± 0.21700.060 ± 0.1229
Calcium: On IV therapy (Day 11)0.030 ± NA——
Calcium: End of IV therapy-0.020 ± 0.24110.071 ± 0.19640.078 ± 0.0930
Calcium: Test of Cure0.235 ± 0.26270.096 ± 0.20570.128 ± 0.1114
Calcium: Early Follow-up0.276 ± 0.13830.120 ± 0.09190.142 ± 0.1232
Calcium: Late Follow-up0.243 ± 0.09220.115 ± 0.10270.110 ± 0.1538
C02 content/Bicarbonate: On IV therapy (Day 5)-1.7 ± 3.010.0 ± 2.83-2.0 ± 0.00
C02 content/Bicarbonate: On IV therapy (Day 11)-3.0 ± NA——
C02 content/Bicarbonate: End of IV therapy-2.4 ± 2.070.6 ± 2.30-0.3 ± 2.88
C02 content/Bicarbonate: Test of Cure-0.8 ± 1.722.7 ± 1.801.4 ± 4.28
C02 content/Bicarbonate: Early Follow-up0.0 ± 3.810.3 ± 1.63-0.4 ± 4.72
C02 content/Bicarbonate: Late Follow-up0.7 ± 2.341.8 ± 2.711.2 ± 4.97
Chloride: On IV therapy (Day 5)1.2 ± 4.071.8 ± 3.503.7 ± 1.15
Chloride: On IV therapy (Day 11)4.0 ± NA——
Chloride: End of IV therapy1.0 ± 3.743.0 ± 3.83-0.2 ± 2.32
Chloride: Test of Cure0.5 ± 3.941.0 ± 3.830.2 ± 2.28
Chloride: Early Follow-up0.6 ± 4.720.5 ± 4.510.0 ± 2.35
Chloride: Late Follow-up0.3 ± 4.18-0.5 ± 3.022.2 ± 0.84
Glucose: On IV therapy (Day 5)0.42 ± 1.9932.25 ± 1.700-2.00 ± 2.685
Glucose: On IV therapy (Day 11)1.50 ± NA——
Glucose: End of IV therapy-1.06 ± 1.3721.09 ± 1.542-0.68 ± 2.741
Glucose: Test of Cure-0.35 ± 1.649-0.11 ± 1.173-0.24 ± 2.261
Glucose: Early Follow-up-0.80 ± 1.1580.07 ± 1.316-0.78 ± 1.949
Glucose: Late Follow-up-0.45 ± 1.1060.58 ± 1.703-0.56 ± 2.395
Potassium: On IV therapy (Day 5)0.52 ± 0.662-0.05 ± 0.6450.37 ± 0.666
Potassium: On IV therapy (Day 11)0.00 ± NA——
Potassium: End of IV therapy0.46 ± 0.6230.24 ± 0.5090.48 ± 0.407
Potassium: Test of Cure0.78 ± 0.7390.40 ± 0.5260.44 ± 0.351
Potassium: Early Follow-up0.40 ± 0.7250.50 ± 0.4000.42 ± 0.327
Potassium: Late Follow-up0.28 ± 0.4710.53 ± 0.5470.40 ± 0.495
Sodium: On IV therapy (Day 5)1.2 ± 2.230.3 ± 2.752.3 ± 2.52
Sodium: On IV therapy (Day 11)4.0 ± NA——
Sodium: End of IV therapy0.4 ± 2.791.7 ± 3.15-0.8 ± 2.14
Sodium: Test of Cure1.8 ± 1.331.3 ± 3.401.0 ± 1.73
Sodium: Early Follow-up1.8 ± 3.27-0.5 ± 3.451.0 ± 1.58
Sodium: Late Follow-up1.2 ± 3.54-1.2 ± 4.362.0 ± 2.65
Urea/BUN: On IV therapy (Day 5)-0.98 ± 2.024-0.45 ± 1.515-0.97 ± 0.874
Urea/BUN: On IV therapy (Day 11)-2.50 ± NA——
Urea/BUN: End of IV therapy-0.30 ± 2.633-1.13 ± 1.367-0.57 ± 1.046
Urea/BUN: Test of Cure-0.38 ± 1.184-0.73 ± 1.456-0.38 ± 1.033
Urea/BUN: Early Follow-up-0.64 ± 1.3050.20 ± 2.262-0.34 ± 0.853
Urea/BUN: Late Follow-up-0.30 ± 0.716-0.33 ± 1.199-0.12 ± 1.932
PrimaryChange From Baseline in Clinical Laboratory Parameters- Alanine Amino Transferase (ALT), Alkaline Phosphatase (ALP), Aspartate Amino Transferase (AST), Creatine Kinase and Gamma Glutamyl Transferase (GGT)

Clinical laboratory parameters included ALT, ALP, AST, Creatine kinase and GGT. Baseline was Day 1. Change from Baseline was calculated by subtracting Baseline values from individual post-Baseline values. Mean change from Baseline up to Late follow-up visit in ALT, ALP, AST, Creatine kinase and GGT are presented.

Time frame:
Baseline (Day 1) to Late Follow up Visit (21 to 28 days post-IV therapy)
Reported as:
Mean · International units per Liter
Change From Baseline in Clinical Laboratory Parameters- Alanine Amino Transferase (ALT), Alkaline Phosphatase (ALP), Aspartate Amino Transferase (AST), Creatine Kinase and Gamma Glutamyl Transferase (GGT)
International units per LiterGSK2251052 750 mgGSK2251052 1500 mgImipenem-Cilastatin
ALT: On IV therapy (Day 3)5.7 ± 8.1410.4 ± 21.5312.8 ± 11.19
ALT: On IV therapy (Day 5)33.2 ± 46.824.8 ± 8.8513.3 ± 17.90
ALT: On IV therapy (Day 8)4.0 ± NA1.5 ± 6.36-3.0 ± NA
ALT: On IV therapy (Day 11)2.0 ± NA——
ALT: End of IV therapy35.4 ± 40.4618.6 ± 21.3521.3 ± 29.30
ALT: Test of Cure17.5 ± 18.537.3 ± 10.347.0 ± 10.12
ALT: Early Follow-up4.8 ± 5.971.0 ± 5.335.8 ± 7.40
ALT: Late Follow-up3.3 ± 5.99-0.3 ± 4.324.2 ± 5.50
ALP: On IV therapy (Day 3)10.8 ± 26.3314.3 ± 30.1213.2 ± 28.28
ALP: On IV therapy (Day 5)11.2 ± 22.994.0 ± 27.1417.7 ± 35.50
ALP: On IV therapy (Day 8)-10.0 ± NA21.5 ± 12.02-10.0 ± NA
ALP: On IV therapy (Day 11)-11.0 ± NA——
ALP: End of IV therapy7.4 ± 26.2816.3 ± 34.6210.2 ± 22.60
ALP: Test of Cure10.8 ± 23.476.9 ± 15.0414.8 ± 17.01
ALP: Early Follow-up7.4 ± 21.011.2 ± 23.738.2 ± 12.01
ALP: Late Follow-up5.7 ± 20.642.3 ± 13.813.6 ± 13.13
AST: On IV therapy (Day 3)5.0 ± 12.074.1 ± 12.5819.2 ± 16.04
AST: On IV therapy (Day 5)31.5 ± 57.166.3 ± 13.3820.0 ± 34.66
AST: On IV therapy (Day 8)-2.0 ± NA2.0 ± 0.002.0 ± NA
AST: On IV therapy (Day 11)2.0 ± NA——
AST: End of IV therapy22.0 ± 34.7113.1 ± 15.0815.7 ± 23.34
AST: Test of Cure1.5 ± 9.81-2.3 ± 4.54-1.4 ± 6.50
AST: Early Follow-up-1.2 ± 8.56-4.8 ± 10.341.2 ± 6.76
AST: Late Follow-up3.3 ± 15.02-3.3 ± 10.073.4 ± 2.88
Creatine kinase : On IV therapy (Day 5)-76.0 ± 118.58-37.8 ± 46.94-26.0 ± 18.33
Creatine kinase : On IV therapy (Day 11)4.0 ± NA——
Creatine kinase : End of IV therapy-36.0 ± 33.56-165.6 ± 407.70-23.7 ± 18.33
Creatine kinase : Test of Cure-65.3 ± 129.24-156.4 ± 420.0018.4 ± 18.80
Creatine kinase : Early Follow-up-41.4 ± 158.04-218.2 ± 495.53-6.0 ± 30.12
Creatine kinase : Late Follow-up-37.8 ± 134.80-168.8 ± 448.900.2 ± 41.05
GGT : On IV therapy (Day 5)41.7 ± 49.616.5 ± 8.2724.0 ± 35.68
GGT : On IV therapy (Day 11)22.0 ± NA——
GGT : End of IV therapy35.8 ± 49.9628.9 ± 39.8814.0 ± 20.27
GGT : Test of Cure16.5 ± 20.6723.3 ± 24.693.6 ± 8.76
GGT : Early Follow-up-1.4 ± 36.908.3 ± 13.54-0.8 ± 12.15
GGT : Late Follow-up-16.7 ± 54.701.3 ± 9.58-3.8 ± 12.03
PrimaryNumber of Participants With Adverse Events (AE) and Serious Adverse Events (SAE)

AE is any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product. For marketed medicinal products, this also includes failure to produce expected benefits (i.e., lack of efficacy), abuse or misuse. SAE is any untoward medical occurrence that, at any dose results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, or is a congenital anomaly/birth defect or is medically significant.

Time frame:
Up to 28 days post-therapy
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events (AE) and Serious Adverse Events (SAE)
ParticipantsGSK2251052 750 mgGSK2251052 1500 mgImipenem-Cilastatin
AE565
SAE120
PrimaryNumber of Participants With Abnormal Electrocardiogram (ECG) Findings

Twelve lead ECGs were obtained during the study using an ECG machine that automatically measured PR, QRS, QT, and QT corrected by Bazett's formula (QTcB), QT corrected by Fridericia's formula (QTcF) intervals. Twelve lead ECGs were performed with the participant in a semi-supine position having rested in this position for at least 10 minutes beforehand. Measurements that deviated substantially from previous readings were repeated immediately. Three measurements were taken at pre-dose on Day 1 at least 5 min apart. One additional ECG measurement was taken after completion of the first infusion of study medication. Two ECG measurements (pre and post-1st infusion of the day) were taken on Day 4 while the participant was on IV therapy. When there was an abnormal finding, two more were taken and the mean PR interval, QRS duration, QT interval and QTcB were calculated from automated ECG readings. One ECG measurement was taken at the early safety follow-up visit.

Time frame:
Up to Late Follow-up Visit (21 to 28 days post-IV therapy)
Reported as:
Count of participants · Participants
Number of Participants With Abnormal Electrocardiogram (ECG) Findings
ParticipantsGSK2251052 750 mgGSK2251052 1500 mgImipenem-Cilastatin
Day 1: Pre-dose 1042
Day 1: Pre-dose 2242
Day 1: Pre-dose 3123
Day 1: Post-dose153
Day 4 (on IV treatment): Pre-dose242
Day 4 (on IV treatment): Post-dose332
Early Follow-up032
Withdrawal000
PrimarySummary of Vital Signs: Mean Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)

Vital sign measurements included SBP and DBP (supine or semi-supine). Measurements that deviated substantially from previous readings were repeated immediately. Mean SBP and DBP are presented.

Time frame:
Up to Late Follow up Visit (21 to 28 days post-IV therapy)
Reported as:
Mean · Millimeters of mercury (mmHg)
Summary of Vital Signs: Mean Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)
Millimeters of mercury (mmHg)GSK2251052 750 mgGSK2251052 1500 mgImipenem-Cilastatin
SBP: Baseline (Day 1)129.7 ± 29.27131.9 ± 14.56120.0 ± 17.64
SBP: On IV therapy (Day 2)131.2 ± 15.20125.4 ± 15.89120.0 ± 19.75
SBP: On IV therapy (Day 3)123.8 ± 15.09126.6 ± 28.69123.8 ± 13.88
SBP: On IV therapy (Day 4)137.8 ± 17.61127.0 ± 30.79124.2 ± 17.98
SBP: On IV therapy (Day 5)135.2 ± 27.58126.6 ± 35.10116.8 ± 18.42
SBP: On IV therapy (Day 6)150.0 ± NA125.5 ± 34.65115.0 ± 12.25
SBP: On IV therapy (Day 7)165.0 ± NA125.0 ± 21.21116.7 ± 20.82
SBP: On IV therapy (Day 8)170.0 ± NA125.0 ± 49.50110.0 ± NA
SBP: On IV therapy (Day 9)161.0 ± NA130.0 ± NA105.0 ± NA
SBP: On IV therapy (Day 10)140.0 ± NA—110.0 ± NA
SBP: On IV therapy (Day 11)155.0 ± NA——
SBP: On IV therapy (Day 12)140.0 ± NA——
SBP: On IV therapy (Day 13)130.0 ± NA——
SBP: On IV therapy (Day 14)152.0 ± NA——
SBP: End of IV therapy130.0 ± 17.03116.1 ± 13.93117.5 ± 11.73
SBP: Test of Cure131.3 ± 5.85126.9 ± 27.17126.4 ± 20.12
SBP: Early Follow-up128.0 ± 17.03120.1 ± 15.24123.8 ± 13.10
SBP: Late Follow-up148.0 ± 23.64117.6 ± 21.77116.6 ± 13.35
DBP: Baseline (Day 1)68.0 ± 12.8477.3 ± 9.2566.5 ± 4.64
DBP: On IV therapy (Day 2)78.3 ± 12.8269.0 ± 15.6170.3 ± 10.78
DBP: On IV therapy (Day 3)77.2 ± 12.2272.1 ± 15.7271.2 ± 3.56
DBP: On IV therapy (Day 4)85.5 ± 15.7379.5 ± 19.4169.6 ± 5.77
DBP: On IV therapy (Day 5)83.8 ± 13.9579.7 ± 21.8967.0 ± 4.12
DBP: On IV therapy (Day 6)90.0 ± NA81.0 ± 12.7372.5 ± 15.00
DBP: On IV therapy (Day 7)85.0 ± NA70.0 ± 0.0067.7 ± 9.29
DBP: On IV therapy (Day 8)90.0 ± NA69.0 ± 15.5670.0 ± NA
DBP: On IV therapy (Day 9)95.0 ± NA80.0 ± NA65.0 ± NA
DBP: On IV therapy (Day 10)69.0 ± NA—70.0 ± NA
DBP: On IV therapy (Day 11)69.0 ± NA——
DBP: On IV therapy (Day 12)75.0 ± NA——
DBP: On IV therapy (Day 13)80.0 ± NA——
DBP: On IV therapy (Day 14)69.0 ± NA——
DBP: End of IV therapy74.0 ± 9.9469.4 ± 17.2271.5 ± 12.42
DBP: Test of Cure82.2 ± 5.8870.6 ± 12.4771.8 ± 15.14
DBP: Early Follow-up73.8 ± 9.6272.0 ± 11.7268.8 ± 12.05
DBP: Late Follow-up87.7 ± 16.1867.5 ± 16.1365.0 ± 5.29
PrimarySummary of Vital Signs- Mean Heart Rate

Vital sign measurements included heart rate. Measurements that deviated substantially from previous readings were repeated immediately. Mean heart rate is presented.

Time frame:
Up to Late Follow-up Visit (21 to 28 days post-IV therapy)
Reported as:
Mean · Beats per minute
Summary of Vital Signs- Mean Heart Rate
Beats per minuteGSK2251052 750 mgGSK2251052 1500 mgImipenem-Cilastatin
Baseline (Day 1)85.8 ± 10.6399.3 ± 13.7887.7 ± 11.78
On IV therapy (Day 2)78.2 ± 12.8083.0 ± 18.9781.5 ± 4.23
On IV therapy (Day 3)77.8 ± 4.9280.6 ± 14.7981.4 ± 9.40
On IV therapy (Day 4)78.5 ± 11.4581.0 ± 10.4373.6 ± 12.10
On IV therapy (Day 5)72.3 ± 13.5280.3 ± 10.5568.2 ± 11.45
On IV therapy (Day 6)89.0 ± NA92.0 ± 16.9774.8 ± 6.70
On IV therapy (Day 7)81.0 ± NA88.5 ± 16.2678.3 ± 9.07
On IV therapy (Day 8)88.0 ± NA87.5 ± 6.3682.0 ± NA
On IV therapy (Day 9)84.0 ± NA80.0 ± NA85.0 ± NA
On IV therapy (Day 10)91.0 ± NA—86.0 ± NA
On IV therapy (Day 11)100.0 ± NA——
On IV therapy (Day 12)84.0 ± NA——
On IV therapy (Day 13)90.0 ± NA——
On IV therapy (Day 14)92.0 ± NA——
End of IV therapy72.8 ± 11.8282.8 ± 8.9171.0 ± 7.32
Test of Cure74.5 ± 11.8673.6 ± 11.9474.6 ± 15.34
Early Follow-up72.5 ± 11.5774.0 ± 14.9965.8 ± 8.90
Late Follow-up76.8 ± 13.0671.8 ± 11.1178.2 ± 11.19
PrimarySummary of Vital Signs- Mean Respiration Rate

Vital sign measurements included respiratory rate. Measurements that deviated substantially from previous readings were repeated immediately. Mean respiration rate are presented.

Time frame:
Up to Late Follow-up Visit (21 to 28 days post-IV therapy)
Reported as:
Mean · Breaths/minute
Summary of Vital Signs- Mean Respiration Rate
Breaths/minuteGSK2251052 750 mgGSK2251052 1500 mgImipenem-Cilastatin
Baseline (Day 1)17.3 ± 2.9419.6 ± 3.8517.3 ± 3.27
On IV therapy (Day 2)15.0 ± 1.6718.1 ± 3.6816.8 ± 3.03
On IV therapy (Day 3)14.2 ± 1.3316.6 ± 3.6216.8 ± 4.27
On IV therapy (Day 4)15.5 ± 0.8417.3 ± 3.9917.8 ± 4.35
On IV therapy (Day 5)14.5 ± 1.5216.6 ± 3.4618.8 ± 3.59
On IV therapy (Day 6)16.0 ± NA17.0 ± 4.2416.0 ± 4.32
On IV therapy (Day 7)16.0 ± NA16.5 ± 3.5417.3 ± 4.16
On IV therapy (Day 8)16.0 ± NA15.0 ± 1.4120.0 ± NA
On IV therapy (Day 9)14.0 ± NA16.0 ± NA22.0 ± NA
On IV therapy (Day 10)17.0 ± NA—20.0 ± NA
On IV therapy (Day 11)15.0 ± NA——
On IV therapy (Day 12)16.0 ± NA——
On IV therapy (Day 13)14.0 ± NA——
On IV therapy (Day 14)14.0 ± NA——
End of IV therapy16.0 ± 2.4515.8 ± 2.9616.4 ± 2.19
Test of Cure14.0 ± 1.7915.5 ± 3.4218.2 ± 4.15
Early Follow-up15.3 ± 1.9715.9 ± 3.5216.4 ± 3.21
Late Follow-up13.4 ± 1.9516.0 ± 2.7816.6 ± 3.71
PrimarySummary of Vital Signs- Mean Temperature

Vital sign measurements included temperature (oral, tympanic or rectal). Measurements that deviated substantially from previous readings were repeated immediately. Temperature was assessed as normal hospital practice dictated and the maximum daily temperature was recorded in the electronic case report form (eCRF).

Time frame:
Up to Late Follow up Visit (21 to 28 days post-IV therapy)
Reported as:
Mean · Celsius
Summary of Vital Signs- Mean Temperature
CelsiusGSK2251052 750 mgGSK2251052 1500 mgImipenem-Cilastatin
Baseline (Day 1)38.08 ± 0.74138.41 ± 0.94638.30 ± 0.469
On IV therapy (Day 2)36.97 ± 1.06337.30 ± 0.69337.30 ± 0.860
On IV therapy (Day 3)36.75 ± 0.70636.79 ± 0.38037.74 ± 0.817
On IV therapy (Day 4)36.60 ± 0.46936.71 ± 0.66937.38 ± 0.986
On IV therapy (Day 5)36.27 ± 0.37836.59 ± 0.49836.96 ± 0.654
On IV therapy (Day 6)37.00 ± NA36.90 ± 1.27336.40 ± 0.283
On IV therapy (Day 7)36.20 ± NA36.95 ± 0.77836.93 ± 0.416
On IV therapy (Day 8)36.80 ± NA36.80 ± 0.70736.50 ± NA
On IV therapy (Day 9)36.50 ± NA36.80 ± NA36.50 ± NA
On IV therapy (Day 10)37.00 ± NA—36.50 ± NA
On IV therapy (Day 11)37.00 ± NA——
On IV therapy (Day 12)36.80 ± NA——
On IV therapy (Day 13)36.20 ± NA——
On IV therapy (Day 14)36.80 ± NA——
End of IV therapy36.18 ± 0.51236.75 ± 0.67636.38 ± 0.299
Test of Cure36.25 ± 0.41835.98 ± 0.70936.14 ± 0.744
Early Follow-up36.23 ± 0.42735.99 ± 0.38736.28 ± 0.606
Late Follow-up36.40 ± 0.11036.08 ± 0.51236.00 ± 0.394
PrimaryTherapeutic Response at the Test of Cure Visit

The therapeutic response was the combination of a participant's clinical and microbiological response. It was assessed at the Test of Cure visit in participants who have a qualifying Gram-negative uropathogen at Baseline and have had a minimum of 5 days of IV therapy. Therapeutic response was a measure of the overall efficacy response, and a therapeutic success referred to participants who have been deemed both a 'clinical success' and a 'microbiological success'. All other combinations (other than 'clinical success' + 'microbiological success') were deemed failures for therapeutic response.

Time frame:
Test of Cure Visit (5 to 9 days post-IV therapy)
Reported as:
Count of participants · Participants
Therapeutic Response at the Test of Cure Visit
ParticipantsGSK2251052 750 mgGSK2251052 1500 mgImipenem-Cilastatin
Therapeutic Success151
Therapeutic Failure534
PrimaryChange From Baseline in Hematology Parameters- Hematocrit

Hematology parameters included hematocrit. Baseline was Day 1. Change from Baseline was calculated by subtracting Baseline values from individual post-Baseline values. Mean change from Baseline up to Late follow-up visit in hematocrit are presented.

Time frame:
Baseline (Day 1) to Late Follow up Visit (21 to 28 days post-IV therapy)
Reported as:
Mean · Fraction
Change From Baseline in Hematology Parameters- Hematocrit
FractionGSK2251052 750 mgGSK2251052 1500 mgImipenem-Cilastatin
End of IV therapy-0.0140 ± 0.06893-0.0155 ± 0.06930-0.0120 ± 0.02993
Late Follow-up0.0373 ± 0.03079-0.0007 ± 0.03322-0.0038 ± 0.01669
PrimaryChange From Baseline in Hematology Parameters- Mean Corpuscle Hemoglobin (MCH)

Hematology parameters included MCH. Baseline was Day 1. Change from Baseline was calculated by subtracting Baseline values from individual post-Baseline values. Mean change from Baseline up to Late follow-up visit in MCH are presented.

Time frame:
Baseline (Day 1) to Late Follow up Visit (21 to 28 days post-IV therapy)
Reported as:
Mean · Picograms
Change From Baseline in Hematology Parameters- Mean Corpuscle Hemoglobin (MCH)
PicogramsGSK2251052 750 mgGSK2251052 1500 mgImipenem-Cilastatin
End of IV therapy-0.60 ± 0.748-0.60 ± 0.668-0.07 ± 0.628
Late Follow-up-0.85 ± 0.657-0.89 ± 0.573-0.14 ± 0.472
PrimaryChange From Baseline in Hematology Parameters- Mean Corpuscle Volume (MCV)

Hematology parameters included MCV. Baseline was Day 1. Change from Baseline was calculated by subtracting Baseline values from individual post-Baseline values. Mean change from Baseline up to Late follow-up visit in MCV are presented.

Time frame:
Baseline (Day 1) to Late Follow up Visit (21 to 28 days post-IV therapy)
Reported as:
Mean · Femtoliters
Change From Baseline in Hematology Parameters- Mean Corpuscle Volume (MCV)
FemtolitersGSK2251052 750 mgGSK2251052 1500 mgImipenem-Cilastatin
End of IV therapy-3.0 ± 2.45-1.3 ± 1.98-1.0 ± 0.89
Late Follow-up-2.2 ± 0.98-1.3 ± 2.75-0.8 ± 1.79
PrimaryChange From Baseline in Hematology Parameters- Red Blood Cell (RBC) Count and Reticulocytes

Hematology parameters included RBC count and reticulocytes. Baseline was Day 1. Change from Baseline was calculated by subtracting Baseline values from individual post-Baseline values. Mean change from Baseline up to Late follow-up visit in RBC count and reticulocytes are presented.

Time frame:
Baseline (Day 1) to Late Follow up Visit (21 to 28 days post-IV therapy)
Reported as:
Mean · Trillion cells per liter
Change From Baseline in Hematology Parameters- Red Blood Cell (RBC) Count and Reticulocytes
Trillion cells per literGSK2251052 750 mgGSK2251052 1500 mgImipenem-Cilastatin
RBC: End of IV therapy-0.10 ± 0.689-0.10 ± 0.707-0.08 ± 0.360
RBC: Late Follow-up0.52 ± 0.3660.07 ± 0.2360.02 ± 0.228
Reticulocytes: End of IV therapy-0.0331 ± 0.04544-0.0312 ± 0.02489-0.0072 ± 0.02295
Reticulocytes: Late Follow-up-0.0466 ± 0.09881-0.0092 ± 0.032670.0080 ± 0.02577
PrimaryChange From Baseline in Hematology Parameters- Hemoglobin and Mean Corpuscle Hemoglobin Concentration (MCHC)

Hematology parameters included hemoglobin and MCHC. Baseline was Day 1. Change from Baseline was calculated by subtracting Baseline values from individual post-Baseline values. Mean change from Baseline up to Late follow-up visit in hemoglobin and MCHC are presented.

Time frame:
Baseline (Day 1) to Late Follow up Visit (21 to 28 days post-IV therapy)
Reported as:
Mean · Gram per Liter
Change From Baseline in Hematology Parameters- Hemoglobin and Mean Corpuscle Hemoglobin Concentration (MCHC)
Gram per LiterGSK2251052 750 mgGSK2251052 1500 mgImipenem-Cilastatin
Hemoglobin: End of IV therapy-3.0 ± 22.77-5.5 ± 21.36-2.5 ± 8.17
Hemoglobin: Late Follow-up11.0 ± 7.24-2.1 ± 9.67-0.6 ± 4.16
MCHC: End of IV therapy4.0 ± 3.81-1.8 ± 6.504.2 ± 6.74
MCHC: Late Follow-up-3.0 ± 8.44-5.0 ± 5.941.8 ± 8.29
PrimaryChange From Baseline in Hematology Parameters- Basophils, Eosinophils, Lymphocytes, Monocytes, Platelet Count, Total Neutrophils and White Blood Cell Count (WBC)

Hematology parameters included basophils, eosinophils, lymphocytes, monocytes, platelet count, total neutrophils and WBC. Baseline was Day 1. Change from Baseline was calculated by subtracting Baseline values from individual post-Baseline values. Mean change from Baseline up to Late follow-up visit in basophils, eosinophils, lymphocytes, monocytes, platelet count, total neutrophils and WBC are presented.

Time frame:
Baseline (Day 1) to Late Follow up Visit (21 to 28 days post-IV therapy)
Reported as:
Mean · Gigacells per Liter
Change From Baseline in Hematology Parameters- Basophils, Eosinophils, Lymphocytes, Monocytes, Platelet Count, Total Neutrophils and White Blood Cell Count (WBC)
Gigacells per LiterGSK2251052 750 mgGSK2251052 1500 mgImipenem-Cilastatin
Basophils: End of IV therapy0.028 ± 0.00840.018 ± 0.01160.014 ± 0.0182
Basophils: Late Follow-up0.022 ± 0.01470.020 ± 0.01630.016 ± 0.0114
Eosinophils: End of IV therapy0.274 ± 0.13890.096 ± 0.09800.090 ± 0.0682
Eosinophils: Late Follow-up0.093 ± 0.14880.067 ± 0.09660.086 ± 0.0385
Lymphocytes: End of IV therapy0.580 ± 1.20760.514 ± 0.38160.596 ± 0.5140
Lymphocytes: Late Follow-up0.687 ± 1.51910.774 ± 0.48080.436 ± 0.7578
Monocytes: End of IV therapy-0.188 ± 0.3739-0.256 ± 0.2015-0.442 ± 0.3841
Monocytes: Late Follow-up-0.380 ± 0.4553-0.230 ± 0.3902-0.186 ± 0.2103
Platelet count: End of IV therapy141.0 ± 171.5883.2 ± 139.06105.4 ± 92.20
Platelet count: Late Follow-up48.8 ± 129.1045.4 ± 34.9339.8 ± 35.81
Total neutrophils: End of IV therapy-8.178 ± 3.6642-6.695 ± 4.6214-4.656 ± 6.6652
Total neutrophils: Late Follow-up-6.765 ± 4.0488-7.737 ± 6.3494-7.902 ± 8.1795
WBC count: End of IV therapy-7.48 ± 4.242-6.30 ± 4.607-4.36 ± 6.696
WBC count: Late Follow-up-6.33 ± 4.918-7.11 ± 6.207-7.54 ± 8.486
SecondaryMicrobiological Response at the End of IV Therapy Visit, Test of Cure Visit and Late Follow-Up Visit

Microbiological response involved both microbiological success and microbiological failure. A reduction in the uropathogens in the urine culture and no growth on blood culture was termed as microbiological success. Increase in the uropathogens in the urine culture and pathogens identified in the blood culture or use of antibacterials other than study treatments were classified as microbiological failures.

Time frame:
End of IV therapy (0-24 hours post-therapy), Test of Cure Visit (5 to 9 days post-IV therapy) and Late Follow-up (21-28 days post-therapy)
Reported as:
Count of participants · Participants
Microbiological Response at the End of IV Therapy Visit, Test of Cure Visit and Late Follow-Up Visit
ParticipantsGSK2251052 750 mgGSK2251052 1500 mgImipenem-Cilastatin
End of IV therapy — Microbiological Success355
End of IV therapy — Microbiological Failure330
Test of Cure — Microbiological Success151
Test of Cure — Microbiological Failure534
Late Folllow-up — Microbiological Success261
Late Folllow-up — Microbiological Failure424
SecondaryClinical Response at the End of IV Therapy Visit, Test of Cure Visit and Late Follow-Up Visit

Clinical response was a combination of clinical success and clinical failure. In clinical success, participants showed no signs and symptoms of pyelonephritis and lower complicated urinary tract infection and antibiotics are not used for the same. In clinical failure, there is reappearance of signs and symptoms of and lower complicated urinary tract infection and participant required antibiotics for the same.

Time frame:
End of IV therapy (0-24 hours post-therapy), Test of Cure Visit (5 to 9 days post-IV therapy) and Late Follow-up (21-28 days post-therapy)
Reported as:
Count of participants · Participants
Clinical Response at the End of IV Therapy Visit, Test of Cure Visit and Late Follow-Up Visit
ParticipantsGSK2251052 750 mgGSK2251052 1500 mgImipenem-Cilastatin
End of IV therapy — Clinical Success465
End of IV therapy — Clinical Failure220
Test of Cure — Clinical Success464
Test of Cure — Clinical Failure221
Late Follow-up — Clinical Success362
Late Follow-up — Clinical Failure323
SecondaryTherapeutic Response (Combined Clinical and Microbiological Response) at the End of IV Visit and Late Follow-Up Visit

The therapeutic response was the combination of a participant's clinical and microbiological response. It was assessed at the Test of Cure visit in participants who have a qualifying Gram-negative uropathogen at Baseline and have had a minimum of 5 days of IV therapy. Therapeutic response was a measure of the overall efficacy response, and a therapeutic success referred to participants who have been deemed both a 'clinical success' and a 'microbiological success'. All other combinations (other than 'clinical success' + 'microbiological success') were deemed failures for therapeutic response.

Time frame:
End of IV therapy (0-24 hours post-therapy) and Late Follow-up (21-28 days post-therapy)
Reported as:
Count of participants · Participants
Therapeutic Response (Combined Clinical and Microbiological Response) at the End of IV Visit and Late Follow-Up Visit
ParticipantsGSK2251052 750 mgGSK2251052 1500 mgImipenem-Cilastatin
End of IV therapy — Therapeutic Success355
End of IV therapy — Therapeutic Failure330
Late Follow-up — Therapeutic Success261
Late Follow-up — Therapeutic Failure424
SecondaryMaximum Plasma Concentration (Cmax) of GSK2251052

The planned pharmacokinetic (PK) and PK/pharmacodynamic analyses were not performed, because the PK data was not collected.

Time frame:
Day 3: Pre- dose (just prior to the start of the first infusion of the day) and 1 hour (just prior to the end of the infusion), 2, 4, and 12 hours post-dose

No measurements were reported for this outcome.

SecondaryArea Under the Concentration Time Curve (AUC) of GSK2251052

The planned pharmacokinetic (PK) and PK/pharmacodynamic analyses were not performed, because the PK data was not collected.

Time frame:
Day 3: Pre- dose (just prior to the start of the first infusion of the day) and 1 hour (just prior to the end of the infusion), 2, 4, and 12 hours post-dose

No measurements were reported for this outcome.

SecondaryTime to Cmax (Tmax) of GSK2251052

The planned pharmacokinetic (PK) and PK/pharmacodynamic analyses were not performed, because the PK data was not collected.

Time frame:
Day 3: Pre- dose (just prior to the start of the first infusion of the day) and 1 hour (just prior to the end of the infusion), 2, 4, and 12 hours post-dose

No measurements were reported for this outcome.

SecondaryCmax of GSK2251052 Using Non-intensive PK Sampling

The planned pharmacokinetic (PK) and PK/pharmacodynamic analyses were not performed, because the PK data was not collected.

Time frame:
Day 4: Pre- dose (just prior to the start of the first infusion of the day) and 1 hour (just prior to the end of the infusion), 2, 4, and 12 hours post-dose

No measurements were reported for this outcome.

SecondaryAUC of GSK2251052 Using Non-intensive PK Sampling

The planned pharmacokinetic (PK) and PK/pharmacodynamic analyses were not performed, because the PK data was not collected.

Time frame:
Day 4: Pre- dose (just prior to the start of the first infusion of the day) and 1 hour (just prior to the end of the infusion), 2, 4, and 12 hours post-dose

No measurements were reported for this outcome.

SecondaryTmax of GSK2251052 Using Non-intensive PK Sampling

The planned pharmacokinetic (PK) and PK/pharmacodynamic analyses were not performed, because the PK data was not collected.

Time frame:
Day 4: Pre- dose (just prior to the start of the first infusion of the day) and 1 hour (just prior to the end of the infusion), 2, 4, and 12 hours post-dose

No measurements were reported for this outcome.

SecondaryCmax of GSK2251052 Using Intensive PK Sampling

The planned pharmacokinetic (PK) and PK/pharmacodynamic analyses were not performed, because the PK data was not collected.

Time frame:
Day 4: Pre-dose (just prior to the start of the first infusion of the day) 0.5, 1 hour (just prior to the end of the infusion), 1.25, 1.5, 2, 3, 4, 8 and 12 hours post-dose

No measurements were reported for this outcome.

SecondaryAUC of GSK2251052 Using Intensive PK Sampling

The planned pharmacokinetic (PK) and PK/pharmacodynamic analyses were not performed, because the PK data was not collected.

Time frame:
Day 4: Pre-dose (just prior to the start of the first infusion of the day) 0.5, 1 hour (just prior to the end of the infusion), 1.25, 1.5, 2, 3, 4, 8 and 12 hours post-dose

No measurements were reported for this outcome.

SecondaryTmax of GSK2251052 Using Intensive PK Sampling

The planned pharmacokinetic (PK) and PK/pharmacodynamic analyses were not performed, because the PK data was not collected.

Time frame:
Day 4: Pre-dose (just prior to the start of the first infusion of the day) 0.5, 1 hour (just prior to the end of the infusion), 1.25, 1.5, 2, 3, 4, 8 and 12 hours post-dose

No measurements were reported for this outcome.

Adverse events

Collected over Up to 28 days post-therapy. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
GSK2251052 750 mg0/6 (0%)1/6 (16.7%)5/6 (83.3%)
GSK2251052 1500 mg0/8 (0%)2/8 (25%)5/8 (62.5%)
Imipenem-Cilastatin0/6 (0%)0/6 (0%)5/6 (83.3%)
Most frequent serious events
Most frequent serious events
EventGSK2251052 750 mgGSK2251052 1500 mgImipenem-Cilastatin
Pulmonary embolismRespiratory, thoracic and mediastinal disorders1/60/80/6
Aspiration bronchialInvestigations0/61/80/6
Haemoglobin decreasedInvestigations0/61/80/6
Cardiac arrestCardiac disorders0/61/80/6
Escherichia bacteraemiaInfections and infestations0/61/80/6
Most frequent other events
Showing 10 of 25
Most frequent other events
EventGSK2251052 750 mgGSK2251052 1500 mgImipenem-Cilastatin
DizzinessNervous system disorders1/60/82/6
HeadacheNervous system disorders0/60/82/6
NauseaGastrointestinal disorders0/62/81/6
Alanine aminotransferase increasedInvestigations1/62/80/6
Abdominal pain upperGastrointestinal disorders0/60/81/6
DyspepsiaGastrointestinal disorders0/60/81/6
Rectal haemorrhageGastrointestinal disorders0/60/81/6
ParaesthesiaNervous system disorders1/60/80/6
PharyngitisInfections and infestations1/60/81/6
Oral herpesInfections and infestations1/60/80/6

Baseline characteristics

Age, Continuous
Age, Continuous(Years)GSK2251052 750 mgGSK2251052 1500 mgImipenem-CilastatinTotal
Mean55.7 ± 13.6050.4 ± 24.4548.0 ± 17.4851.3 ± 18.95
Sex: Female, Male
Sex: Female, Male(Participants)GSK2251052 750 mgGSK2251052 1500 mgImipenem-CilastatinTotal
Female34310
Male34310
Race (NIH/OMB)
Race (NIH/OMB)(Participants)GSK2251052 750 mgGSK2251052 1500 mgImipenem-CilastatinTotal
American Indian or Alaska Native0112
Asian0000
Native Hawaiian or Other Pacific Islander0000
Black or African American0101
White66517
More than one race0000
Unknown or Not Reported0000
08

Study locations

24 sites
  • GSK Investigational Site
    Los Angeles, California 90033, United States
  • GSK Investigational Site
    Council Bluffs, Iowa 51503, United States
  • GSK Investigational Site
    Topeka, Kansas 66604, United States
  • GSK Investigational Site
    Corsicana, Texas 75110, United States
  • GSK Investigational Site
    Chicoutimi, Quebec G7H 5H6, Canada
  • GSK Investigational Site
    Sherbrooke, Quebec J1H 5N4, Canada
  • GSK Investigational Site
    Suresnes, 92151, France
  • GSK Investigational Site
    Toulouse cedex 9, 31059, France
  • GSK Investigational Site
    Athens, 11527, Greece
  • GSK Investigational Site
    Chaidari, 12462, Greece
  • GSK Investigational Site
    Goudi, Athens, 11527, Greece
  • GSK Investigational Site
    Thessaloniki, 56429, Greece
  • GSK Investigational Site
    Irkutsk, 664079, Russian Federation
  • GSK Investigational Site
    Moscow, 125367, Russian Federation
  • GSK Investigational Site
    Rostov-on-Don, 344022, Russian Federation
  • GSK Investigational Site
    Smolensk, 214018, Russian Federation
  • GSK Investigational Site
    St'Petersburg, 194354, Russian Federation
  • GSK Investigational Site
    Alicante, 03010, Spain
  • GSK Investigational Site
    Elche (Alicante), 03203, Spain
  • GSK Investigational Site
    Getafe/Madrid, 28905, Spain
  • GSK Investigational Site
    Granada, 18003, Spain
  • GSK Investigational Site
    Madrid, 28040, Spain
  • GSK Investigational Site
    Murcia, Spain
  • GSK Investigational Site
    Pama de Mallorca, 07010, Spain
09

References and documents

Publications

  • O'Dwyer K, Spivak AT, Ingraham K, Min S, Holmes DJ, Jakielaszek C, Rittenhouse S, Kwan AL, Livi GP, Sathe G, Thomas E, Van Horn S, Miller LA, Twynholm M, Tomayko J, Dalessandro M, Caltabiano M, Scangarella-Oman NE, Brown JR. Bacterial resistance to leucyl-tRNA synthetase inhibitor GSK2251052 develops during treatment of complicated urinary tract infections. Antimicrob Agents Chemother. 2015 Jan;59(1):289-98. doi: 10.1128/AAC.03774-14. Epub 2014 Oct 27. PubMed 25348524 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2011 to primary completion in Mar 2012, 8 months.

Results were first posted in Sep 2017, 5 years 6 months after primary completion. A results delay was requested in Nov 2012.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 9, 2011
First posted
Jun 27, 2011
StartActual
Jun 28, 2011
Primary completionActual
Mar 6, 2012
CompletionActual
Mar 6, 2012
Results delay requested
Nov 15, 2012
Results first posted
Sep 8, 2017
Last update
Sep 8, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 8, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01381549
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Jun 27, 2011
Start date
Jun 28, 2011
Primary completion
Mar 6, 2012
Completion
Mar 6, 2012
Results posted
Sep 8, 2017
Last update
Sep 8, 2017

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Aug 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Epetraborole

Start the discussion